Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.42 |
| ▸ | CSF1R | P07333 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1116014 | 0.89 | MAPT (0.46) | MAPTMAPK14CSF1RKMT2AMEN1 | |
| SCHEMBL2926922 | 0.88 | MAPT (0.44) | MAPTCSF1RKMT2AMEN1KDM4E | |
| SCHEMBL1115894 | 0.88 | MAPT (0.44) | MAPTMAPK14CSF1RKMT2AMEN1 | |
| SCHEMBL1115898 | 0.88 | MAPT (0.44) | MAPTMAPK14CSF1RKMT2AMEN1 | |
| SCHEMBL1115897 | 0.85 | MAPT (0.42) | MAPTMAPK14CSF1RKMT2AMEN1 | |
| SCHEMBL1115889 | 0.81 | MAPT (0.43) | MAPTMAPK14CSF1RKMT2AMEN1 | |
| SCHEMBL1115902 | 0.79 | FABP3 (0.45) | MAPTCSF1RKMT2AMEN1 | |
| SCHEMBL1116255 | 0.77 | MAPT (0.46) | MAPTKMT2AMEN1KDM4EPTGS2 | |
| SCHEMBL12856603 | 0.75 | MAPT (0.46) | MAPTKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL12856631 | 0.75 | MAPT (0.44) | MAPTCSF1RKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910314-B1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20080306064-A1 | Benzimidazole Derivatives | BROWN LYNDON NIGEL | 2008-12-11 | — | — | US | disclosed |
| EP-1910314-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | Novartis AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009774-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306064-A1 | Benzimidazole Derivatives | PPARG, PPARD, BRD4 | MAPT 2716/4885MAPK14 1676/4885CSF1R 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.